Neurocrine Biosciences, Inc. - Common Stock (NBIX)

145.35
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 3rd, 9:19 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close145.35
Open-
Bid157.00
Ask158.00
Day's RangeN/A - N/A
52 Week Range122.14 - 186.12
Volume3,693
Market Cap14.72B
PE Ratio (TTM)27.17
EPS (TTM)5.4
Dividend & YieldN/A (N/A)
1 Month Average Volume1,257,082

Chart

About Neurocrine Biosciences, Inc. - Common Stock (NBIX)

Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More

News & Press Releases

Neurocrine (NBIX) Q3 2026 Earnings Call Transcriptfool.com
Record $1.1B revenue marks transformative quarter for diversified biotech.
Via The Motley Fool · November 2, 2026
Neurocrine Biosciences Q3 Earnings Call Highlightsmarketbeat.com
Neurocrine Biosciences (NASDAQ:NBIX) reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines: INGREZZA, CRENESSITY and VYKAT XR. Chief Executive Officer Kyle Gano said the company’s commercial
Via MarketBeat · November 2, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Q3 Earnings Beat as INGREZZA Guidance Raisedchartmill.com
Via Chartmill · November 2, 2026
After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket Reviewchartmill.com
Via Chartmill · November 2, 2026
Neurocrine Biosciences (NASDAQ:NBIX): A Debt-Free GARP Stock With Reasonable Growthchartmill.com
Via Chartmill · November 2, 2026
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuationchartmill.com
Via Chartmill · October 28, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stockchartmill.com
Via Chartmill · October 5, 2026
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuationchartmill.com
Via Chartmill · October 2, 2026
Where Will Neurocrine Biosciences Be in 5 Years?fool.com
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Via The Motley Fool · October 25, 2026
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.
By FN Media · Via GlobeNewswire · October 21, 2026
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END
Via FinancialNewsMedia · October 21, 2026
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuationchartmill.com
Via Chartmill · August 29, 2026
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discountchartmill.com
Via Chartmill · August 5, 2026
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hitmarketbeat.com
Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify beyond its largest product, INGREZZA. Gano said China has become both a com
Via MarketBeat · September 23, 2026
Neurocrine (NBIX) Q2 2026 Earnings Call Transcriptfool.com
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via The Motley Fool · August 3, 2026
Neurocrine Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The
Via MarketBeat · July 31, 2026
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setupchartmill.com
Via Chartmill · July 27, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stockchartmill.com
Via Chartmill · July 25, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setupchartmill.com
Via Chartmill · July 20, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screeningchartmill.com
Via Chartmill · July 16, 2026
Neurocrine (NBIX) Q2 2026 Earnings Call Transcriptfool.com
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via The Motley Fool · July 30, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screenchartmill.com
Via Chartmill · July 11, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screenchartmill.com
Via Chartmill · July 4, 2026
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setupchartmill.com
Via Chartmill · July 1, 2026
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Frameworkchartmill.com
Via Chartmill · June 24, 2026